ORPHA:566192
Congenital autosomal recessive small-platelet thrombocytopenia
Also known as: CARST
Publications
107
59.5th percentile
Trials
0
Interventional, condition-specific
Researchers
504
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare isolated constitutional thrombocytopenia characterized by onset of small-platelet thrombocytopenia with significantly increased bleeding tendency. Bleeding symptoms include petechial rash, mucosal bleeding, and heavy menstrual bleeding. Growth and development are normal, and there is no increased susceptibility to infections.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0035441
- UMLS:C5680129
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
107 matched papers (68 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPartial
None under the specific name; 615 for broader category thrombocytopenia
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
107
107 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
107 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
68 in the last 10 years · high confidence · 59.5th percentile (publications denominator)
Phrase hits: 107 · MeSH hits: 0
Who's working on it?
504
Distinct author names in 107 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Li Y10 papers · 2024
Institute of Clinical Pharmacology, Peking University First Hospital, Beijing, China. liyun03602@pkufh.com.
Papers in Europe PMC - 02Mathuthu M9 papers · 2026
Center for Applied Radiation Science and Tehnology, North West University (Mafikeng), P.Bag X2046, Mmabatho 2735, South Africa. Manny.Mathuthu@nwu.ac.za.
Papers in Europe PMC - 03Wang Y7 papers · 2025
Beijing Advanced Innovation Center for Food Nutrition and Human Health, College of Veterinary Medicine, China Agricultural University, Beijing, China.
Papers in Europe PMC - 04Lv Y6 papers · 2023
Institute of Clinical Pharmacology, Peking University First Hospital, Beijing, China lvyuan0901@sina.com walshtr@cardiff.ac.uk.
Papers in Europe PMC - 05Cui L4 papers · 2023
Institute of Clinical Pharmacology, Peking University First Hospital, Beijing, China.
Papers in Europe PMC - 06Dudu VP3 papers · 2025
North-West University, Centre for Applied Radiation, Science and Technology (CARST), Private Bag X2046, Mmabatho, 2735, South Africa.
Papers in Europe PMC - 07Li R3 papers · 2025
Department of Dermatology and Venerology, Peking University First Hospital, National Clinical Research Center for Skin and Immune Diseases, Research Center for Medical Mycology, Peking University, Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, People's Republic of China.
Papers in Europe PMC - 08Liu W3 papers · 2025
Department of Pediatrics, The Second Affiliated Hospital of Anhui Medical University, No. 678 Furong Road, Hefei City, 230601, Anhui Province, China.
Papers in Europe PMC - 09Olukotun SF3 papers · 2026
Department of Physics and Engineering Physics, Obafemi Awolowo University, Ile-Ife, Nigeria. olukotunsf@oauife.edu.ng.
Papers in Europe PMC - 10Song Y3 papers · 2023
State Key Laboratory of Microbial Resources, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 615 trials are registered for thrombocytopenia, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
615 interventional trials matched thrombocytopenia, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: thrombocytopenia
615
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT06412497·RECRUITING·MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.
Conditions: Severe Aplastic Anemia · Acquired Amegakaryocytic Thrombocytopenia · Acquired Pure Red Cell Aplasia · Paroxysmal Nocturnal Hemoglobinuria·Matched via name phrase
- NCT07687134·NOT YET RECRUITING·Eltrombopag Plus Telitacicept vs. Eltrombopag Alone for Steroid-refractory/Relapsed ITP
Conditions: Immune Thrombocytopenia·Matched via name phrase
- NCT06673498·RECRUITING·Lusutrombopag Combined With Recombinant Human Thrombopoietin for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Destined to Undergo Elective Invasive Surgery
Conditions: Thrombocytopenia·Matched via name phrase
- NCT07599280·NOT YET RECRUITING·Universal STAR-T Cell Injection in R/R Autoimmune Diseases.
Conditions: Immune Thrombocytopenia·Matched via name phrase
- NCT06533098·RECRUITING·A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
Conditions: Thrombocytopenia, Neonatal Alloimmune·Matched via name phrase
- NCT07362238·RECRUITING·Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)
Conditions: Immune Thrombocytopenia · Treatment·Matched via name phrase
- NCT07700238·NOT YET RECRUITING·A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP)
Conditions: Primary Immune Thrombocytopenia·Matched via name phrase
- NCT07603557·NOT YET RECRUITING·Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE)
Conditions: Chronic Immune Thrombocytopenia · Autoimmune Hemolytic Anemia·Matched via name phrase
- NCT07586813·RECRUITING·Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors
Conditions: Persistent Isolated Chemotherapy-Induced Thrombocytopenia · Chemotherapy-Induced Thrombocytopenia · Gastrointestinal Neoplasms · Pancreatic Cancer·Matched via name phrase
- NCT06202625·RECRUITING·Efficacy and Safety of Avatrombopag in the Treatment of Thrombocytopenia After Haplo-HSCT
Conditions: Thrombocytopenia · Stem Cell Transplant Complications·Matched via name phrase
- NCT07549698·RECRUITING·Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease
Conditions: Warm Autoimmune Hemolytic Anemia (WAIHA) · ITP - Immune Thrombocytopenia · Warm Autoimmune Hemolytic Anemia · Immune Thrombocytopenic Purpura·Matched via name phrase
- NCT06886516·RECRUITING·Apixaban in Thrombocytopenia
Conditions: Deep Vein Thrombosis · Pulmonary Embolism and Thrombosis · Thrombocytopenia · Recurrent Venous Thromboembolism·Matched via name phrase
- NCT06788691·RECRUITING·Luspatercept for Clonal Cytopenias of Uncertain Significance
Conditions: CCUS Clonal Cytopenia of Undetermined Significance · Anemia · Leukopenia · Thrombocytopenia·Matched via name phrase
- NCT07278908·NOT YET RECRUITING·Avatrombopag Combined With All-trans Retinoic Acid in the Treatment of Primary Immune Thrombocytopenia
Conditions: ITP - Immune Thrombocytopenia·Matched via name phrase
- NCT06658834·RECRUITING·A Study of Romiplostim N01 as the First-line Treatment for Newly Diagnosed Adult Patients With ITP
Conditions: Primary Immune Thrombocytopenia·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Congenital autosomal recessive small-platelet thrombocytopenia" OR "CARST"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Congenital autosomal recessive small-platelet thrombocytopenia" OR "CARST"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"thrombocytopenia"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T18:26:03.731Z
